Clene (CLNN) Competitors $5.95 +0.36 (+6.44%) Closing price 04:00 PM EasternExtended Trading$5.90 -0.05 (-0.84%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLNN vs. ENGN, GNFT, CRGX, ACIU, HRTX, OGI, AARD, IPHA, LYEL, and CGTXShould you be buying Clene stock or one of its competitors? The main competitors of Clene include enGene (ENGN), GENFIT (GNFT), CARGO Therapeutics (CRGX), AC Immune (ACIU), Heron Therapeutics (HRTX), Organigram Global (OGI), Aardvark Therapeutics (AARD), Innate Pharma (IPHA), Lyell Immunopharma (LYEL), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry. Clene vs. Its Competitors enGene GENFIT CARGO Therapeutics AC Immune Heron Therapeutics Organigram Global Aardvark Therapeutics Innate Pharma Lyell Immunopharma Cognition Therapeutics enGene (NASDAQ:ENGN) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends. Which has better earnings and valuation, ENGN or CLNN? Clene has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioenGeneN/AN/A-$55.14M-$1.65-3.03Clene$340K174.83-$39.40M-$3.76-1.58 Do insiders and institutionals have more ownership in ENGN or CLNN? 64.2% of enGene shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 10.4% of enGene shares are owned by insiders. Comparatively, 35.3% of Clene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is ENGN or CLNN more profitable? enGene has a net margin of 0.00% compared to Clene's net margin of -10,386.36%. Clene's return on equity of 0.00% beat enGene's return on equity.Company Net Margins Return on Equity Return on Assets enGeneN/A -32.60% -28.26% Clene -10,386.36%N/A -125.49% Which has more risk & volatility, ENGN or CLNN? enGene has a beta of -0.39, suggesting that its stock price is 139% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Do analysts recommend ENGN or CLNN? enGene currently has a consensus price target of $23.29, indicating a potential upside of 365.71%. Clene has a consensus price target of $33.00, indicating a potential upside of 454.62%. Given Clene's stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than enGene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Clene 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media prefer ENGN or CLNN? In the previous week, enGene had 6 more articles in the media than Clene. MarketBeat recorded 11 mentions for enGene and 5 mentions for Clene. Clene's average media sentiment score of 0.42 beat enGene's score of -0.08 indicating that Clene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Neutral Clene 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryClene beats enGene on 9 of the 15 factors compared between the two stocks. Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLNN vs. The Competition Export to ExcelMetricCleneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.85M$3.13B$5.75B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-1.5820.8978.4326.42Price / Sales174.83458.96546.94119.09Price / CashN/A44.5237.0558.92Price / Book-5.619.9310.916.06Net Income-$39.40M-$53.38M$3.29B$266.28M7 Day Performance9.98%0.05%0.01%-0.76%1 Month Performance59.09%7.08%7.06%3.83%1 Year Performance-10.66%11.92%50.09%24.39% Clene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLNNClene3.6819 of 5 stars$5.95+6.4%$33.00+454.6%-5.6%$55.85M$340K-1.58100News CoverageGap UpENGNenGene3.18 of 5 stars$4.30-0.5%$23.29+441.5%-27.5%$220.77MN/A0.0031News CoverageUpcoming EarningsShort Interest ↓Gap UpGNFTGENFIT2.3808 of 5 stars$4.19-4.5%$9.00+115.1%-4.3%$219.08M$76.77M0.00120Gap DownCRGXCARGO Therapeutics1.6828 of 5 stars$4.47flat$15.40+244.5%N/A$216.17MN/A-0.96116ACIUAC Immune2.1539 of 5 stars$2.07-3.7%$12.00+479.7%-26.1%$215.88M$31.02M-3.57140News CoverageHRTXHeron Therapeutics4.3261 of 5 stars$1.38-1.4%$4.50+226.1%-23.1%$214.61M$144.29M-69.00300OGIOrganigram Global1.2493 of 5 stars$1.63+1.9%N/A-9.5%$214.48M$117.47M32.61860AARDAardvark TherapeuticsN/A$9.04-7.5%$32.80+262.8%N/A$211.98MN/A0.0018News CoverageHigh Trading VolumeIPHAInnate Pharma2.8885 of 5 stars$2.20-2.0%$11.00+399.1%-9.4%$207.41M$21.77M0.00220Short Interest ↓LYELLyell Immunopharma3.6667 of 5 stars$10.97+2.0%$15.00+36.7%-59.2%$206.71M$60K-0.45270News CoveragePositive NewsAnalyst UpgradeShort Interest ↓CGTXCognition Therapeutics1.1583 of 5 stars$3.18+13.2%$2.83-10.9%+273.8%$206.46MN/A0.0020News CoverageHigh Trading Volume Related Companies and Tools Related Companies ENGN Competitors GNFT Competitors CRGX Competitors ACIU Competitors HRTX Competitors OGI Competitors AARD Competitors IPHA Competitors LYEL Competitors CGTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLNN) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredNewegg (NEGG) Earns BULLISH Rating – Up 934%The last time he shared a free AI stock pick like this, it soared 100%.Chaikin Analytics | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLNN Stock Alerts